Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
BS01 in Patients With Retinitis Pigmentosa
NCTID
NCT04278131
(View at clinicaltrials.gov)
Description
Non-randomized, open label, Phase 1/2 dose escalation study of BS01, a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP).
(Show More)
Development Status
Active
Indication
Retinitis Pigmentosa
Disease Ontology Term
DOID:10584
Compound Name
BS01
Compound Description
AAV2-CAG-ChronosFP-WPRE
Sponsor
Bionic Sight LLC
Funder Type
Industry
Recruitment Status
Recruiting
Enrollment Count
20
Results Posted
Not Available
Therapy Information
Target Gene/Variant
ChronosFP
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Overexpression of protective allele/gene
Route of Administration
Intravitreal
Drug Product Type
Viral vector
Target Tissue/Cell
Retinal ganglion
Delivery System
Viral transduction
Vector Type
AAV2
Editor Type
Dose 1
Dose escalation with 4 levels, unknown concentrations
Dose 2
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Phase1, Phase2
Submit Date
2020-02-13
Completion Date
2029-12-30
Last Update
2023-05-03
Participation Criteria
Eligible Age
>=18 Years
Standard Ages
Adult, Older adult
Sexes Eligible for Study
ALL
Locations
No.of Trial Sites
1
Locations
United States
Regulatory Information
Has US IND
True
FDA Designations
Regenerative Medicine Advanced Therapy
Recent Updates
Gene therapy product is coupled with a neural circuit, retinal prosthesis
Resources/Links
Clinical Publications
(Video) Positive Interim Results in Bionic Sight's Optogenetic Gene Therapy Trial
News and Press Releases
Bionic Sight's BS01 Gene Therapy Receives RMAT Designation from the FDA
Bionic Sight Reports Meaningful Vision Improvements for RP Patients Receiving Highest Dose of its Emerging Optogenetic Therapy
First Four Patients In Bionic Sight's Optogenetic Gene Therapy Trial Are Able To Detect Light And Motion
Preclinical Publications
A clinically viable approach to restoring visual function using optogenetic gene therapy
Retinal prosthetic strategy with the capacity to restore normal vision
Maintaining ocular safety with light exposure, focusing on devices for optogenetic stimulation
An Engineering Platform for Clinical Application of Optogenetic Therapy in Retinal Degenerative Diseases